Regeneron Acquires 23andMe for $256 Million

TARRYTOWN, N.Y., May 19, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has won the auction for 23andMe, acquiring the struggling company for $256 million. The deal, confirmed Monday, includes major business lines, such as 23andMe’s Personal Genome Service and Biobank.

The acquisition comes as 23andMe navigates bankruptcy proceedings. Regeneron intends to maintain the customer services offered by 23andMe without interruption. This strategic purchase is expected to close in the third quarter of 2025, pending bankruptcy court and regulatory approvals.

“This acquisition enables us to enhance our genetics-guided research and drug development while supporting 23andMe’s mission,” said George D. Yancopoulos, M.D., Ph.D., co-founder and Chief Scientific Officer of Regeneron. Regeneron has experience handling genetic data from nearly 3 million participants and is committed to protecting customer privacy and data security.

The newly acquired assets will help Regeneron strengthen its existing research capabilities. A spokesperson from Regeneron stated they will work with a court-appointed Customer Privacy Ombudsman to ensure compliance with privacy laws and maintain the trust of 23andMe’s customers.

Joe Selsavage, Interim CEO of 23andMe, expressed optimism about the deal, stating, “We are pleased to reach an agreement with a science-driven partner that helps ensure our mission will carry forward.” Regeneron’s expertise in genetic data management positions them to further both companies’ ambitions in the field of genetics.